Skip to main content
Journal cover image

Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials.

Publication ,  Journal Article
Kiernan, MS; Stevens, SR; Tang, WHW; Butler, J; Anstrom, KJ; Birati, EY; Grodin, JL; Gupta, D; Margulies, KB; LaRue, S; Dávila-Román, VG ...
Published in: J Card Fail
July 2018

BACKGROUND: Poor response to loop diuretic therapy is a marker of risk during heart failure hospitalization. We sought to describe baseline determinants of diuretic response and to further explore the relationship between this response and clinical outcomes. METHODS AND RESULTS: Patient data from the National Heart, Lung, and Blood Institute Heart Failure Network ROSE-AHF and CARRESS-HF clinical trials were analyzed to determine baseline determinants of diuretic response. Diuretic efficiency (DE) was defined as total 72-hour fluid output per total equivalent loop diuretic dose. Data from DOSE-AHF was then used to determine if these predictors of DE correlated with response to a high- versus low-dose diuretic strategy. At 72 hours, the high-DE group had median fluid output of 9071 ml (interquartile range: 7240-11775) with median furosemide dose of 320 mg (220-480) compared with 8030 ml (6300-9915) and 840 mg (600-1215) respectively for the low DE group. Cystatin C was independently associated with DE (odds ratio 0.36 per 1mg/L increase; 95% confidence interval: 0.24-0.56; P < 0.001). Independently from baseline characteristics, reduced fluid output, weight loss and DE were each associated with increased 60 day mortality. Among patients with estimated glomerular filtration rate below the median, those randomized to a high-dose strategy had improved symptoms compared with those randomized to a low-dose strategy. CONCLUSIONS: Elevated baseline cystatin C, as a biomarker of renal dysfunction, is associated with reduced diuretic response during heart failure hospitalization. Higher loop diuretic doses are required for therapeutic decongestion in patients with renal insufficiency. Poor response identifies a high-risk population.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Card Fail

DOI

EISSN

1532-8414

Publication Date

July 2018

Volume

24

Issue

7

Start / End Page

428 / 438

Location

United States

Related Subject Headings

  • United States
  • Sodium Potassium Chloride Symporter Inhibitors
  • Prognosis
  • National Heart, Lung, and Blood Institute (U.S.)
  • Middle Aged
  • Male
  • Humans
  • Hospitalization
  • Heart Failure
  • Furosemide
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Kiernan, M. S., Stevens, S. R., Tang, W. H. W., Butler, J., Anstrom, K. J., Birati, E. Y., … NHLBI Heart Failure Clinical Trials Network Investigators, . (2018). Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. J Card Fail, 24(7), 428–438. https://doi.org/10.1016/j.cardfail.2018.02.002
Kiernan, Michael S., Susanna R. Stevens, WH Wilson Tang, Javed Butler, Kevin J. Anstrom, Edo Y. Birati, Justin L. Grodin, et al. “Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials.J Card Fail 24, no. 7 (July 2018): 428–38. https://doi.org/10.1016/j.cardfail.2018.02.002.
Kiernan, Michael S., et al. “Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials.J Card Fail, vol. 24, no. 7, July 2018, pp. 428–38. Pubmed, doi:10.1016/j.cardfail.2018.02.002.
Kiernan MS, Stevens SR, Tang WHW, Butler J, Anstrom KJ, Birati EY, Grodin JL, Gupta D, Margulies KB, LaRue S, Dávila-Román VG, Hernandez AF, de Las Fuentes L, NHLBI Heart Failure Clinical Trials Network Investigators. Determinants of Diuretic Responsiveness and Associated Outcomes During Acute Heart Failure Hospitalization: An Analysis From the NHLBI Heart Failure Network Clinical Trials. J Card Fail. 2018 Jul;24(7):428–438.
Journal cover image

Published In

J Card Fail

DOI

EISSN

1532-8414

Publication Date

July 2018

Volume

24

Issue

7

Start / End Page

428 / 438

Location

United States

Related Subject Headings

  • United States
  • Sodium Potassium Chloride Symporter Inhibitors
  • Prognosis
  • National Heart, Lung, and Blood Institute (U.S.)
  • Middle Aged
  • Male
  • Humans
  • Hospitalization
  • Heart Failure
  • Furosemide